Zobrazeno 1 - 10
of 65
pro vyhledávání: ''
Autor:
Qingwei Luo, Roberta De Angelis, Nehmat Houssami, Dianne L. O'Connell, Xue Qin Yu, Clare Kahn
Publikováno v:
BMC Cancer
Background Breast cancer places a heavy burden on the Australian healthcare system, but information about the actual number of women living with breast cancer and their current or future health service needs is limited. We used existing population-ba
Autor:
Yalai Bai, William M. Sikov, David L. Rimm, Maysa M. Abu-Khalaf, Lyndsay Harris, Veerle Bossuyt, Huan Cheng, Natalie Sinclair
Publikováno v:
BMC Cancer
Background Preoperative therapy with chemotherapy and the HER2-targeted monoclonal antibody trastuzumab is valuable for patients with large or locally advanced HER2-positive (HER2+) breast cancers but traditional methods of measuring HER2 expression
Autor:
Anupam Batra, C. Michael DiPersio, Anshu Aggarwal, David M. Jones, Rami N. Al-Rohil, Paul J. Feustel
Publikováno v:
BMC Cancer
Background Expression of integrin α3β1 is associated with tumor progression, metastasis, and poor prognosis in several cancers, including breast cancer. Moreover, preclinical studies have revealed important pro-tumorigenic and pro-metastatic functi
Publikováno v:
BMC Cancer
Background A signal transduction pathway (STP) is a network of intercellular information flow initiated when extracellular signaling molecules bind to cell-surface receptors. Many aberrant STPs have been associated with various cancers. To develop op
Autor:
Nicole Lavender, Jiqing Sai, Ann Richmond, Philip Owens, Jinming Yang, C. Andrew Johnson, Gregory D. Ayers, Sheau-Chiann Chen
Publikováno v:
BMC Cancer
Background The role of the chemokine CCL2 in breast cancer is controversial. While CCL2 recruits and activates pro-tumor macrophages, it is also reported to enhance neutrophil-mediated anti-tumor activity. Moreover, loss of CCL2 in early development
Autor:
Xue Qin Yu
Publikováno v:
BMC Cancer
BMC Cancer, Vol 9, Iss 1, p 364 (2009)
BMC Cancer, Vol 9, Iss 1, p 364 (2009)
Background Previous studies have documented lower breast cancer survival among women with lower socioeconomic status (SES) in the United States. In this study, I examined the extent to which socioeconomic disparity in breast cancer survival was expla
Autor:
Riikka Nurminen, Johanna Schleutker, Heli Nevanlinna, Liisa M. Pelttari, Lauri A. Aaltonen, Alexandra E. Gylfe
Publikováno v:
BMC Cancer, Vol 12, Iss 1, p 552 (2012)
BMC Cancer
BMC Cancer
Background Rare, heterozygous germline mutations in the RAD51C gene have been found in breast and ovarian cancer families. In the Finnish population, we have identified two founder mutations in RAD51C that increase the risk of ovarian cancer but not
Publikováno v:
BMC Cancer, Vol 10, Iss 1, p 228 (2010)
BMC Cancer
BMC Cancer
Background The 2007 St Gallen international expert consensus statement describes three risk categories and provides recommendations for treatment of early breast cancer. The set of recommendations on how to best treat primary breast cancer is recogni
Autor:
Gina Bouchard, Yves Bérubé-Lauzière, Hélène Therriault, Sameh Geha, Rachel Bujold, Caroline Saucier, Benoit Paquette
Publikováno v:
BMC Cancer
Background Some triple negative breast cancer (TNBC) patients are at higher risk of recurrence in the first three years after treatment. This rapid relapse has been suggested to be associated with inflammatory mediators induced by radiation in health
Autor:
Christine Wilson, Barbara McGillivray, Charmaine Kim-Sing, Stephen Chia, Linlea Armstrong, Andrew J. Coldman, Stuart Peacock, Reka Pataky, Jenna Scott
Publikováno v:
BMC Cancer
Background Women with mutations in BRCA1 or BRCA2 are at high risk of developing breast cancer and, in British Columbia, Canada, are offered screening with both magnetic resonance imaging (MRI) and mammography to facilitate early detection. MRI is mo